for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

European oncology group adds Pharma Mar's Lurbinectedin to treatment guidelines

MADRID, April 15 (Reuters) - Spain’s Pharma Mar said on Thursday that the European Society of Medical Oncology had included its Lurbinectedin drug as a treatment option for small-cell lung cancer patients in its clinical practice guidelines.

Lurbinectedin was approved by Europe’s drug regulator to treat small-cell lung cancer in 2019 and by the U.S. FDA last June.

Reporting by Nathan Allen and Aida Pelaez-Fernandez, editing by Andrei Khalip

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up